Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue.
复制标题
DOI：
10.18632/oncotarget.10765
复制
发表时间：
2016-09-06
期刊：
影响因子：
--
通讯作者：
Silvestris N
中科院分区：
文献类型：
--
作者：
Longo V;Brunetti O;Gnoni A;Cascinu S;Gasparini G;Lorusso V;Ribatti D;Silvestris N
胰腺导管腺癌（PDAC）发生在大多数病例中，诊断时具有早期局部区域扩散和远处转移，导致预后不良，5年总生存率略高于5%。这种恶性肿瘤对化疗和放疗有很大的抵抗力，但其治疗无效的原因尚不清楚。越来越多的证据表明PDAC微环境和血管分布对这种疾病的临床特征有很大的贡献。特别地，PDAC的特征在于与脉管系统塌陷和低氧相关的过度致密的细胞外基质沉积以及低药物递送，这至少部分地解释了抗血管生成药物在这种癌症中的低功效。旨在调节肿瘤间质有利于脉管系统灌注和化疗药物递送的策略正在研究中。
Pancreatic ductal adenocarcinoma (PDAC) occurs in the majority of cases with early loco-regional spread and distant metastases at diagnosis, leading to dismal prognosis with a 5-year overall survival rate moderately over than 5%. This malignancy is largely resistant to chemotherapy and radiation, but the reasons of the refractoriness to the therapies is still unknown. Evidence is accumulating to indicate that the PDAC microenvironment and vascularity strongly contribute to the clinical features of this disease. In particular, PDAC is characterized by excessive dense extracellular matrix deposition associated to vasculature collapse and hypoxia with low drug delivery, explaining at least partly the low efficacy of antiangiogenic drugs in this cancer. Strategies aimed to modulate tumor stroma favoring vasculature perfusion and chemotherapeutics delivery are under investigation.